|
CONTACTS:
Applied NeuroSolutions
Ellen Hoffing, President, CEO, 847-573-8000
or
Investor Relations
Ryan Rauch, 847-573-8000
Applied NeuroSolutions’ Founding Scientist, Dr. Peter Davies, to Participate on Panel at Alzheimer’s Association New York City Chapter’s 20th Annual Meeting
Vernon Hills, IL September 18, 2007 – Applied NeuroSolutions, Inc. (OTC BB:APNS, www.appliedneurosolutions.com), a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer’s disease (AD), today announced Dr. Peter Davies, its founding scientist, and the Judith and Burton P. Resnick Professor of Alzheimer’s Disease Research at Albert Einstein College of Medicine (AECOM), will be participating on a very select panel of AD experts at the Alzheimer’s Association, New York City Chapter’s 20th Annual Meeting.
Dr. Davies will be one of three noted AD experts participating on the panel to discuss the meeting’s theme, “Competing Paradigms In Alzheimer’s Research”. As part of the panel dialogue, Dr. Davies will be making prepared remarks in a presentation titled “Pathways for Developing Treatments for Alzheimer’s Disease”.
The meeting will be on Tuesday, September 25, 2007, and is open to the public. Additional information on the meeting can be found at the Alzheimer’s Association, New York City Chapter web site at www.alznyc.org .
About Applied NeuroSolutions:
Applied NeuroSolutions, Inc. (OTC BB:APNS - News) is developing diagnostics to detect Alzheimer's disease (AD) based on discoveries originating from the Albert Einstein College of Medicine and, in collaboration with Eli Lilly and Company, is developing novel therapeutic compounds to treat the progression of the disease. Applied NeuroSolutions is pursuing biomarkers that the company believes will aid in the development of effective AD treatments. Applied NeuroSolutions is focused on both a cerebrospinal fluid (CSF) diagnostic test and blood tests to detect AD at a very early stage. The CSF test can already differentiate AD patients from those with other diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect Alzheimer's disease. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be 30 million patients. For more information, visit www.appliedneurosolutions.com.
This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.
|
